Tivozanib
Sign in to save this workspacePrimary targets: KDR_VEGFR2 · FDA status: FDA Approved
Selectivity scorecard
KISS
92.42
Gini
0.673
CATDS
0.012
Computed from wild-type kinome inhibition at 1 μM. Gini reproduces the published values within tolerance; KISS and CATDS are computed but pending reconciliation with the paper's reference code.
Polypharmacology radar
Top 20 strongest-inhibited wild-type kinases for Tivozanib. Strongest target: RET at 99.7% inhibition.
Accessible data table
| Rank | Target | Inhibition % | Residual activity % |
|---|---|---|---|
| 1 | RET | 99.7% | 0.3% |
| 2 | C_KIT | 99.4% | 0.6% |
| 3 | KDR_VEGFR2 | 99.3% | 0.7% |
| 4 | FLT4_VEGFR3 | 99.3% | 0.7% |
| 5 | LYN | 99.3% | 0.7% |
| 6 | DDR2 | 99.3% | 0.7% |
| 7 | FMS | 98.6% | 1.4% |
| 8 | EPHA6 | 98.3% | 1.7% |
| 9 | EPHB2 | 98.0% | 2.0% |
| 10 | C_MET | 97.7% | 2.4% |
| 11 | FLT1_VEGFR1 | 97.6% | 2.4% |
| 12 | LCK | 97.5% | 2.5% |
| 13 | BRK | 97.2% | 2.8% |
| 14 | FRK_PTK5 | 97.2% | 2.8% |
| 15 | HCK | 97.1% | 2.9% |
| 16 | DDR1 | 97.1% | 2.9% |
| 17 | PDGFRA | 96.9% | 3.1% |
| 18 | FGR | 96.6% | 3.4% |
| 19 | LOK_STK10 | 96.2% | 3.8% |
| 20 | TRKC | 96.1% | 3.9% |
Selectivity landscape
Where Tivozanib sits in the 92-drug selectivity landscape (KISS vs Gini). The highlighted point is Tivozanib.
Atlas insights for Tivozanib
Pathway-space view of what this drug actually does, drawn from the Pathway Atlas.
On-target vs off-target shadow
On-target0%
Off-target100%
Ghost (2nd-order)0%
| Pathway | Composition | Total |Π| |
|---|---|---|
| ADIPOGENESIS | 2625.29 | |
| ALLOGRAFT_REJECTION | 9325.30 | |
| ANDROGEN_RESPONSE | 1351.13 | |
| ANGIOGENESIS | 1793.42 | |
| APICAL_JUNCTION | 9942.20 | |
| APICAL_SURFACE | 1069.22 | |
| APOPTOSIS | 6687.33 | |
| BILE_ACID_METABOLISM | 1038.51 | |
| CHOLESTEROL_HOMEOSTASIS | 1344.94 | |
| COAGULATION | 1272.21 | |
| COMPLEMENT | 5500.66 | |
| DNA_REPAIR | 1537.00 | |
| E2F_TARGETS | 3331.82 | |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 1595.73 | |
| ESTROGEN_RESPONSE_EARLY | 2877.11 | |
| ESTROGEN_RESPONSE_LATE | 2560.79 | |
| FATTY_ACID_METABOLISM | 853.00 | |
| G2M_CHECKPOINT | 3796.70 | |
| GLYCOLYSIS | 2395.11 | |
| HEDGEHOG_SIGNALING | 1068.51 | |
| HEME_METABOLISM | 1945.63 | |
| HYPOXIA | 4126.82 | |
| IL2_STAT5_SIGNALING | 3226.32 | |
| IL6_JAK_STAT3_SIGNALING | 5343.59 | |
| INFLAMMATORY_RESPONSE | 4461.70 | |
| INTERFERON_ALPHA_RESPONSE | 801.74 | |
| INTERFERON_GAMMA_RESPONSE | 5942.37 | |
| KRAS_SIGNALING_DN | 737.44 | |
| KRAS_SIGNALING_UP | 3354.09 | |
| MITOTIC_SPINDLE | 5949.12 | |
| MTORC1_SIGNALING | 3372.61 | |
| MYC_TARGETS_V1 | 2617.14 | |
| MYC_TARGETS_V2 | 574.59 | |
| MYOGENESIS | 2585.95 | |
| NOTCH_SIGNALING | 188.59 | |
| OXIDATIVE_PHOSPHORYLATION | 1463.84 | |
| P53_PATHWAY | 3304.62 | |
| PANCREAS_BETA_CELLS | 206.60 | |
| PEROXISOME | 958.09 | |
| PI3K_AKT_MTOR_SIGNALING | 9092.68 | |
| PROTEIN_SECRETION | 1942.08 | |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 513.16 | |
| SPERMATOGENESIS | 1137.88 | |
| TGF_BETA_SIGNALING | 1742.13 | |
| TNFA_SIGNALING_VIA_NFKB | 3816.59 | |
| UNFOLDED_PROTEIN_RESPONSE | 1133.76 | |
| UV_RESPONSE_DN | 4894.81 | |
| UV_RESPONSE_UP | 3486.49 | |
| WNT_BETA_CATENIN_SIGNALING | 1581.44 | |
| XENOBIOTIC_METABOLISM | 1802.77 |
Hallmarks-of-Cancer reach
Anti-tumor matches — the "ideal patient" search
| Sample | Cancer type | cos to ideal |
|---|---|---|
| SRR23303752 | — | 0.823 |
| EPT0291 | EPN | 0.814 |
| SRR10899984 | — | 0.809 |
| aMVAC.P_005_TURBT_S223 | — | 0.804 |
| SRR12202498 | — | 0.798 |
Annotations
Sign in to read and post annotations.
Loading…